First filing for Takeda's once-weekly DPP-4 inhibitor but prospects limited?
This article was originally published in Scrip
Executive Summary
Takeda has made the first approval filing for its once-weekly DPP-4 inhibitor trelagliptin (SYR-472), in Japan for the treatment of type 2 diabetes, although some analysts are cautious over its sales prospects despite the apparent convenience benefits.